Search Results

You are looking at 151 - 160 of 4,064 items for :

  • Refine by Access: All x
Clear All
Full access

Kidney Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A

Full access

Telehealth Delivery of Tobacco Cessation Treatment in Cancer Care: An Ongoing Innovation Accelerated by the COVID-19 Pandemic

The Cancer Center Cessation Initiative Telehealth Working Group

replacement. These services required only a telephone and were generally provided free of charge. State-based telephone quitlines have been used to improve access to support for quitting smoking in patients with cancer. 7 However, quitlines typically provide

Full access

Prognostic and Predictive Markers for Patients With Anal Cancer

Emma B. Holliday, Arjun Peddireddy, and Van K. Morris

Squamous cell carcinoma of the anus (SCCA) is a rare cancer with increasing incidence in the United States. It is estimated that >9,000 Americans will be diagnosed with SCCA in 2023. 1 In the past 2 decades, an increasing proportion of patients

Full access

Prostate Cancer Early Detection

Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Prostate cancer is the most commonly diagnosed cancer in American men and the third leading cause of cancer-related deaths. However, the decision whether to pursue early detection of prostate cancer is complex; because not all men with prostate cancer will die of this disease, treatment is not necessary for some. These guidelines are intended to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Meeting Patients Where They Are: Policy Platform for Telehealth and Cancer Care Delivery

Sheetal Kircher, Nicole Braccio, Kathleen Gallagher, Ruth Carlos, Lynne Wagner, Mary Lou Smith, Alan Balch, and Al B. Benson III

The COVID-19 pandemic broadly curtailed access to cancer care and highlighted the need to meet patients “where they are,” which included remote access provisions. This need triggered multiple policy changes in 2020 that have accelerated adoption

Full access

Maintenance of Fitness and Quality-of-Life Benefits From Supervised Exercise Offered as Supportive Care for Breast Cancer

Amy A. Kirkham, Kelcey A. Bland, Holly Wollmann, Alis Bonsignore, Don C. McKenzie, Cheri Van Patten, Karen A. Gelmon, and Kristin Campbell

Background A critical aspect of breast cancer survivorship care includes addressing the negative sequelae of breast cancer therapy on health-related fitness and quality of life (QoL). The NCCN Clinical Practice Guidelines in Oncology (NCCN

Full access

Non–Small Cell Lung Cancer

UCSF Helen Diller Family Comprehensive Cancer Center

Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer cases and includes 3 major types: (1) adenocarcinoma; (2) squamous cell (epidermoid) carcinoma; and (3) large-cell carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States and is also the most frequently occurring cell type in nonsmokers. Important updates to the 2008 guidelines on NSCLC include the addition of tables on drugs and dosing information on chemotherapy regimens for adjuvant therapy.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Prostate Cancer

Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

To properly identify and treat patients with prostate cancer, physicians must have an in-depth understanding of the natural history and diagnostic, staging, and treatment options. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support recommendations. Several variables must be considered in tailoring prostate cancer therapy to each individual patient. These guidelines provide a framework on which to base treatment decisions. Important changes to the guidelines since last publication include the introduction of Principles of Life Expectancy Estimation table and changes in recommendations for both hormone and chemotherapy.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen

Overview Venous thromboembolism (VTE) is a common and life-threatening condition in cancer patients. 1 Results from a recent population-based cohort study showed that the presence of cancer increased the risk for VTE by 9-fold. 2 In a health

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, and Charles C. Williams Jr.

NCCN Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category